Effects of Kanechlor-500 (KC500), a commercial polychlorinated biphenyl mixture, on the levels of serum thyroid hormones such as total thyroxine (T 4 ) and triiodothyronine were examined in male mice, hamsters, rats and guinea pigs. Four days after a single intraperitoneal injection of KC500, significant decreases in the levels of the serum total T 4 and free T 4 occurred in all the animals examined, while a significant decrease in the level of serum triiodothyronine was observed only in guinea pigs among the animals examined. In addition, no significant change in the level of serum thyroid stimulating hormone was observed in any of the rodents examined. A significant increase in the activity of hepatic T 4 -UDP-glucuronosyltransferase after the KC500 administration occurred only in guinea pigs, while the increase in the amount of biliary 
Introduction
There are known species differences among experimental animals in responses to polychlorinated biphenyl (PCB)-derived toxicities, including endocrine disruption, impairments of the reproductive and immune systems, and teratogenicity (Safe, 1994) .
The species differences might be attributed to the differences in the metabolic patterns of PCB congeners and/or the PCB-mediated induction of drug-metabolizing enzymes (Duigman et al., 1987 (Duigman et al., , 1988 .
In general, PCBs, including 3, 3', 4, 4', and Aroclor 1254, have abilities to decrease serum thyroid hormone levels in rats and mice, and the decreases are thought to occur through the induction of thyroxine (T 4 )-UDP-glucuronosyltransferases (UDPGTs) (Barter and Klaassen, 1994; Van Birgelen et al., 1995; Craft et al., 2002) , especially UGT1A1 and UGT1A6 (Visser, 1996) . However, we have previously found that the PCB-mediated reduction of the serum T 4 level in rats and mice is not necessarily correlated with an increase in hepatic T 4 glucuronidation activity (Kato et al., 2003) , that Kanechlor-500 (KC500)-treatment results in a significant decrease in the level of serum total T 4 not only in Wistar rats but also in Gunn rats (UGT1A-deficient Wistar rats) (Kato et al., 2004 (Kato et al., , 2007 , and that the KC500-mediated decrease in rats occurs through an increase in the accumulation level of T 4 in the liver rather than an increase in hepatic T 4 -UDPGT activity (Kato et al., 2007) . To date, however, only limited data are available which would help to explain the mechanism of the PCB-mediated decrease in the level of serum thyroid hormone and its species difference.
In the present study, we examined the KC500-mediated biological alterations, This article has not been copyedited and formatted. The final version may differ from this version. Sciences (Waltham, MA). The KC500 used in the present experiments contains 2,2',5,5'-tetrachlorobiphenyl (5.6% of total PCBs), 2,2',3,5',6-pentachlorobiphenyl (6.5%), 2,2',4,5,5'-pentachlorobiphenyl (10%), 2,3,3',4',6-pentachlorobiphenyl (7.4%), 2,3',4,4',5-pentachlorobiphenyl (7.7%), 2,2',3,4,4',5'-hexachlorobiphenyl (5.6%) and 2,2',4,4',5,5'-hexachlorobiphenyl (5.4%) as major PCB congeners (Haraguchi et al, 2005) . All the other chemicals used were obtained commercially at the highest grade of purity.
Animal Treatments. Male ddy mice (28-36 g), male Syrian hamsters (95-120 g), male
Wistar rats (160-200 g), and male Hartley guinea pigs (400-540 g) were obtained from Japan SLC., Inc. (Shizuoka, Japan). They were housed three or four per cage with free access to commercial chow and tap water, maintained on a 12-h dark/light cycle (8:00 AM to 8:00 PM light) in an air-controlled room (temperature, 24.5 ± 1°C; humidity, 55 ± 5%), and handled with animal care under the guidelines of the University of Shizuoka (Shizuoka, Japan). Mice received a single intraperitoneal injection of KC500 at the desired doses (6.25, 12.5, 25, 37.5, 50 , and 100 mg/kg), and the other animals received an intraperitoneal injection of KC500 (37.5 or 100 mg/kg) dissolved in Panacete 810 (5 ml/kg). Control animals were treated with vehicle alone (5 ml/kg).
This article has not been copyedited and formatted. The final version may differ from this version. In Vivo Study. All animals were killed by decapitation 4 days after the intraperitoneal administration of KC500. The liver was removed, and hepatic microsomes were prepared according to the method of Kato et al. (1995) and stored at -85°C until use. Blood was collected from each animal between 10:30 and 11:30 AM.
After clotting at room temperature, serum was separated by centrifugation and stored at -50°C until use.
Analysis of serum hormones. Levels of total T 4 , free T 4 , total triiodothyronine (T 3 ), and thyroid-stimulating hormone (TSH) were measured by radioimmunoassay using a Total T4 and Free T4 kit (Diagnostic Products Corporation; Los Angeles, CA), T-3 RIABEAD (DAINABOT Co., Ltd, Tokyo, Japan), and the rTSH [ Hepatic microsomal T 4 -UDPGT activity. The amount of hepatic microsomal protein was determined by the method of Lowry et al. (1951) with bovine serum albumin as a standard. The activity of microsomal UDPGT toward T 4 (T 4 -UDPGT activity) was determined by the methods of Barter and Klaassen (1992) .
Ex Vivo Study. Four days after intraperitoneal administration of KC500 the animals were anesthetized with saline solution (2 ml/kg) containing sodium pentobarbital (25 mg/ml) and potassium iodide (1 mg/ml). The femoral artery was cannulated (polyethylene tube SP8, SP10, and SP31; Natsume Inc., Tokyo, Japan) and primed with heparinized saline (33 units/ml). The bile duct was cannulated, and then the animal's This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
Serum Hormone Levels. A dose effect of KC500 on the level of serum total T 4 was first examined in mice 4 days after the chemical treatment ( Figure 1 ). Serum total T 4 levels were significantly decreased by the treatment with KC500 at doses of over 25 mg/kg, and the decrease occurred in a dose-dependent fashion up to 100 mg/kg. The 50% effective dose (ED 50 ) of KC500 for decreasing the level of serum total T 4 was about 37.5 mg/kg. Therefore, 37.5 and/or 100 mg/kg were selected as doses of KC500
in the present experiments.
Treatments of mice, hamsters, rats and guinea pigs with KC500 at a dose of 37.5 mg/kg decreased the total T 4 levels to 63%, 43%, 35% and 27%, respectively, of the corresponding controls ( Figure 2 ). Treatment at a dose of 100 mg/kg resulted in a more effective decrease in the rodents, with the exception of guinea pigs. Likewise, the serum free T 4 level was markedly decreased by KC500 (37.5 mg/kg) in all the rodents examined: 56% of control in mice, 43% of control in hamsters, 24% of control in rats, and 24% of control in guinea pigs. The decrease in each animal species was greater when the KC500 treatment was used at the higher dose (100 mg/kg).
A significant decrease in serum total T 3 level by the treatment with KC500 at a dose of 37.5 mg/kg occurred only in guinea pigs among the species of animals examined ( Figure 3 ). On the other hand, no significant change in the level of serum TSH by the KC500 treatment was observed in any animals examined ( Figure 3 ).
Hepatic T 4 -UDPGT.
The effects of KC500 on hepatic microsomal T 4 -UDPGT activity were examined in mice, hamsters, rats and guinea pigs. A significant increase in the animals, although these increases were observed in the KC500 (37.5 mg/kg)-pretreated rats and guinea pigs but not in the mice and hamsters. The steady-state volumes of distribution in the KC500 (100 mg/kg)-pretreated mice, hamsters, rats and guinea pigs increased to 1.5-times, 4.0-times, 4.1-times and 1.8-times over the corresponding control animals, respectively (Table 1) . and 17% of the [ 125 I]T 4 dosed were accumulated in the liver in the KC500-pretreated mice, hamsters, rats and guinea pigs, respectively (Figure 8 ). In addition, the accumulation level per g of liver was also increased in the KC500-pretreated mice, hamsters, rats and guinea pigs, as compared with the corresponding control animals (Table 2) . Furthermore, KC500-pretreatment led to significant increases in the liver This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
In the present study, we found that treatment with KC500 promoted accumulation of T 4 in several tissues, especially the liver, and resulted in a drastic decrease in the levels of serum total T 4 and free T 4 not only in rats but also in mice, hamsters, and guinea pigs. Incidentally, we have previously reported the KC500-induced decreases in the level of serum total T 4 in the Wistar and Gunn rats (Kato et al., 2004 (Kato et al., , 2007 .
As a possible explanation for the PCB-induced decrease in serum thyroid hormones, a hepatic T 4 -UDPGT-dependent mechanism is generally considered because T 4 -UDPGT inducers, such as Aroclor 1254, TCDD, and CB126, show strong activities for decreasing the levels of serum total thyroid hormones in rats (Barter and Klaassen, 1994; Schuur et al., 1997; Van Birgelen et al., 1995) . However, between mice and rats treated with a T 4 -UDPGT inducer, the differences in magnitude of the decreases in the level of serum total T 4 is not necessarily correlated with that of hepatic T 4 -UDPGT activity (Craft et al., 2002 , Hood et al., 2003 , Kato et al., 2003 . More recently, we have demonstrated that KC500 treatment resulted in significant decreases in the level of serum total T 4 not only in Wistar rats but also in Gunn rats (UGT1A-deficient Wistar rats) (Kato et al., 2004 (Kato et al., , 2007 and further indicated that the KC500-mediated decrease in rats occurred through an increase in the accumulation of T 4 in several tissues, especially the liver, rather than through an increase in hepatic T 4 -UDPGT activity (Kato et al., 2007) . In addition to the previous results, we herein showed that the activity of hepatic T 4 -UDPGT was changed very little by KC500-treatment in mice, hamsters, and rats, although a KC500-mediated decrease in the serum total T 4 level was observed in This article has not been copyedited and formatted. The final version may differ from this version. all the species of animals examined. In addition, no significant changes in the excretion level of biliary T 4 -glucuronide were observed in KC500-pretreated mice, hamsters, and guinea pigs.
A l l
the results obtained herein strongly suggest that the KC500-induced decrease in the serum T 4 level in mice, hamsters, rats, and guinea pigs primarily occurs in a T 4 -UDPGT-independent manner. KC500 treatment led to no significant change in the level of serum TSH in mice, hamsters, rats, and guinea pigs, although serum TSH is considered as one of the factors regulating the level of serum total T 4 . These results are similar with those in previous reports on the effect of PCBs on the level of serum TSH in rats (Hallgren et al., 2001; Hood et al., 1999; Liu et al., 1995 , Kato et al., 2004 , 2007 ).
The factors regulating the level of serum total T 4 , hepatic type-I iodothyronine deiodinase and sulfotransferase are also known. However, hepatic type-I iodothyronine deiodinase activity was significantly decreased by KC500 in rats and hamsters, and furthermore, no significant change in the enzyme activity by treatment with KC500 occurred in either mice or guinea pigs (data not shown). No significant change in the activity of hepatic sulfotransferase was also observed in the KC500-treated mice, hamsters, rats, and guinea pigs (data not shown). Therefore, a KC500-mediated decrease in the serum T 4 level seems to occur in the type-I iodothyronine deiodinaseand sulfotransferase-independent pathways.
As another possible mechanism for the PCB-induced decrease in the level of serum total T 4 , a TTR-associated pathway might also be considered because PCB and its ring-hydroxylated metabolites act as T 4 antagonists to TTR (Lans et al., 1993; Brouwer et al., 1998; Meerts et al., 2002; Kato et al., 2004 (intraperitoneal injection at a dose of 10 mg/kg once daily for 10 days)-pretreated rats (Kato et al., 2007) . The tissue-to-serum concentration ratio (Kp value) was greater in the tissues, especially thyroid gland, liver, kidney, stomach and small intestine, of KC500-pretreated animals than in those of the corresponding control animals. In addition, more than 34%, 55%, 58% and 17% of the [ 125 I]T 4 dosed were accumulated in the liver of the KC500-pretreated mice, hamsters, rats, and guinea pigs, respectively.
In conclusion, we demonstrate for the first time that a KC500-mediated decrease in serum T 4 occurs not only in rats (Kato et al., 2004 (Kato et al., , 2007 , but also in mice, hamsters and guinea pigs and further propose a hypothesis that the PCB-induced decrease occurs through an increase in accumulation (transportation from serum to liver) of T 4 in the liver rather than through induction of hepatic T 4 -UDPGT.
Furthermore, we suggest that the increased accumulation in the liver is attributed, at least in part, to the PCB-and its metabolite(s)-mediated inhibition of formation of the This article has not been copyedited and formatted. The final version may differ from this version. were killed 4 days after the intraperitoneal administration of KC500 (37 and 100 mg/kg), and levels of serum thyroid hormones were measured as described in Materials and
Methods. Constitutive levels: total T 4 , 2.98 ± 0.17 (mice, n=8), 2.67 ± 0.17 (hamsters, n=8), 3.73 ± 0.32 (rats, n=6) and 2.05 ± 0.16 μg/dl (guinea pigs, n=5); free T 4 , 0.43 ± 0.05 (mice, n=8), 1.08 ± 0.08 (hamsters, n=8), 1.47 ± 0.11 (rats, n=6) and 1.44 ± 0.16 ng/dl (guinea pigs, n=5). Each column represents the mean ± S.E. (vertical bars) for four to eight animals. *P<0.05, significantly different from each control. Fig. 3 . Effects of KC500 on the levels of serum total T 3 and TSH in animals. Animals were killed 4 days after the intraperitoneal administration of KC500 (37 mg/kg), and levels of serum thyroid hormones were measured as described in Materials and
Methods. Constitutive levels: total T 3 , 0.38 ± 0.05 (mice, n=6), 0.46 ± 0.02 (hamsters, n=6), 0.59 ± 0.09 (rats, n=6) and 0.25 ± 0.02 ng/ml (guinea pigs, n=6); TSH, 3.50 ± This article has not been copyedited and formatted. The final version may differ from this version. Fig. 4 . Effect of KC500 on the activity of hepatic microsomal T 4 -UDP-GT in animals.
Animals were killed 4 days after the intraperitoneal administration of KC500 (37 mg/kg), and hepatic microsomes from individual animals were used for the T 4 -UDP-GT enzyme assay, as described in Materials and Methods. Figure 6 with noncompartmental methods as described previously (Tabata et al., 1999 
